Ultime notizie per LeMaitre Vascular (NASDAQ:LMAT) Azioni

LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

LeMaitre Vascular Inc

WIIM

LMAT

LeMaitre Vascular shares are trading higher after Barrington Research and Oppenheimer raised their respective price targets on the stock.

Oppenheimer analyst Suraj Kalia reiterates LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $90 to $93.

News

Price Target

Reiteration

Analyst Ratings

Oppenheimer Reiterates Outperform on LeMaitre Vascular, Raises Price Target to $93

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt raised Apple Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $261 to $262. Rosenblatt analyst Barton Crockett maintained a Buy rating. Apple shares closed at $225.91 on Thursday. <a href="https://www.benzinga.com/quote/PATK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised the price target for Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) from $150 to $155. BMO Capital analyst Tristan Thomas-Martin maintained an Outperform rating. Patrick Industries shares closed at $125.98 on Thursday. <a href="https://www.benzinga.com/quote/PATK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Macquarie boosted the price target for Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) from $24 to $30. Macquarie analyst Paul Golding maintained an Outperform rating. Norwegian Cruise Line shares closed at $25.34 on Thursday. <a href="https://www.benzinga.com/quote/NCLH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research increased LeMaitre Vascular, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) price target from $92 to $93. Barrington Research analyst Michael Petusky maintained an Outperform rating. LeMaitre Vascular shares settled at $88.39 on Thursday. <a href="https://www.benzinga.com/quote/LMAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna raised Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $540 to $605. Susquehanna analyst James Friedman maintained a Positive rating. Mastercard shares closed at $499.59 on Thursday. <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Tigress Financial raised Travel + Leisure Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) price target from $58 to $64. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Travel + Leisure shares closed at $47.81 on Thursday. <a href="https://www.benzinga.com/quote/TNL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital increased the price target for Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) from $10 to $11. RBC Capital analyst Douglas Miehm maintained a Sector Perform rating. Bausch Health shares settled at $9.20 on Thursday. <a href="https://www.benzinga.com/quote/BHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie cut Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) price target from $165 to $164. Macquarie analyst Chad Beynon maintained an Outperform rating. Hyatt shares closed at $145.45 on Thursday. <a href="https://www.benzinga.com/quote/MSHFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark increased the price target for The Marcus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) from $20 to $22. Benchmark analyst Mike Hickey maintained a Buy rating. Marcus shares closed at $18.87 on Thursday. <a href="https://www.benzinga.com/quote/MCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group boosted Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $240 to $260. Evercore ISI Group analyst Mark Mahaney maintained an Outperform rating. Amazon shares closed at $186.40 on Thursday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-1024x547.png" alt="" class="wp-image-625906" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5.png 1212w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Markets

Trading Ideas

AAPL

AMZN

NCLH

PATK

Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday

Analysts' ratings for LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high estimate of $100.00, and a low estimate of $92.00. This current average reflects an increase of 9.48% from the previous average price target of $87.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730476854_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive LeMaitre Vascular. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LeMaitre Vascular. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for LeMaitre Vascular's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into LeMaitre Vascular's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
<h2>Get to Know LeMaitre Vascular Better</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 11.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: LeMaitre Vascular's net margin is impressive, surpassing industry averages. With a net margin of 21.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): LeMaitre Vascular's ROE stands out, surpassing industry averages. With an impressive ROE of 3.77%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $92 to $93.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $93

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) raises FY2024 GAAP EPS guidance from $1.82-1.91 to $1.91-1.96 vs $1.85 analyst estimate. Raises FY2024 sales outlook from $216.80 million-220.80 million to $219.00 million-221.00 million vs $218.32 million estimate.

Guidance

LeMaitre Vascular Raises FY2024 GAAP EPS Guidance from $1.82-1.91 to $1.91-1.96 vs $1.85 Est; Raises FY2024 Sales Guidance from $216.80M-220.80M to $219.00M-221.00M vs $218.32M Est

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.44 by 11.36 percent. The company reported quarterly sales of $54.819 million which beat the analyst consensus estimate of $53.503 million by 2.46 percent. This is a 15.63 percent increase over sales of $47.411 million the same period last year.

Earnings

Earnings Beats

LeMaitre Vascular Q3 2024 GAAP EPS $0.49 Beats $0.44 Estimate, Sales $54.819M Beat $53.503M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BTIG analyst Gregory Lewis initiated coverage on DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) with a Buy rating and announced a price target of $16. DHT shares fell 3.2% to close at $11.34 on Monday. <a href="https://www.benzinga.com/quote/DHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Berenberg analyst Nay Soe Naing initiated coverage on Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy rating and announced a price target of $660. Synopsys shares gained 1% to close at $545.46 on Monday. <a href="https://www.benzinga.com/quote/SNPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Ross Osborn initiated coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Neutral rating and announced a price target of $96. LeMaitre Vascular shares gained 1.7% to close at $92.14 on Monday. <a href="https://www.benzinga.com/quote/LMAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Michael Albanese initiated coverage on MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) with a Buy rating and announced a price target of $40. MarineMax shares gained 5.3% to close at $33.13 on Monday. <a href="https://www.benzinga.com/quote/HZO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ryan Levine initiated coverage on Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Neutral rating and announced a price target of $284. Constellation Energy shares gained 2.1% to close at $271.74 on Monday. <a href="https://www.benzinga.com/quote/CEG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SNPS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-1024x500.png" alt="" class="wp-image-596155" style="width:618px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116.png 1357w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one">Jim Cramer Is Worried About This Plane Maker, Says Palo Alto Is A &#8216;Good&#8217; One</a></li>
</ul>

Initiation

SNPS

This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

4 analysts have shared their evaluations of LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated LeMaitre Vascular and provided 12-month price targets. The average target is $95.0, accompanied by a high estimate of $100.00 and a low estimate of $92.00. Marking an increase of 14.91%, the current average surpasses the previous average price target of $82.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728993722_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive LeMaitre Vascular. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LeMaitre Vascular. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of LeMaitre Vascular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into LeMaitre Vascular's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
<h2>Unveiling the Story Behind LeMaitre Vascular</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 11.44%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: LeMaitre Vascular's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For LeMaitre Vascular

Cantor Fitzgerald analyst Ross Osborn initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Neutral rating and announces Price Target of $96.

Cantor Fitzgerald Initiates Coverage On LeMaitre Vascular with Neutral Rating, Announces Price Target of $96

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and maintains $92 price target.

Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $92 Price Target

Acadia Healthcare Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achc#NASDAQ">ACHC</a>) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA. Plans to establish the hospital were announced in July 2023 as part of the joint-venture partnership between ACHC and Omaha-based Methodist Health System. The Methodist Jennie Edmundson Hospital is part of Methodist Health System.&nbsp;
The new facility will be named Methodist Jennie Edmundson Behavioral Health and is likely to commence operations in 2026. It will feature 96 inpatient beds, with 24 specifically designated for addressing the mental health needs of children and adolescents. It will also offer intensive outpatient services. The hospital will invest in cutting-edge technology and resources to enhance access to high-quality behavioral health services for patients dealing with acute mental health and substance use disorders.
This, in turn, is expected to bring about improved health outcomes for residents of western Iowa and eastern Nebraska. Working closely with local organizations, hospitals and first responders of the two regions will enable the joint venture partners to better serve the targeted regions.
<h2>A Time-Opportune Move on ACHC&#39;s Part</h2>
Opening the Methodist Jennie Edmundson Behavioral Health Hospital is likely to be a time-opportune move considering the dire need for acute and intensive outpatient behavioral health services across the Council Bluffs community. According to the American Hospital Directory, there remains a shortage of more than 300 inpatient behavioral health beds in Iowa and Nebraska, which further substantiates the timeliness of the recent move.
<h2>Benefits to Acadia Healthcare</h2>
New facilities resulting from joint ventures offer a means for ACHC to serve a greater number of patients and earn more revenues.&nbsp;
Acadia Healthcare often resorts to buyouts or joint ventures with renowned U.S. health systems to inaugurate new hospitals or expand existing facilities through bed additions. Its healthcare portfolio comprised 258 behavioral healthcare facilities across 38 states and Puerto Rico as of June 30, 2024. Management anticipates adding more than 400 beds to existing facilities in 2024.
<h2>ACHC Stock&#39;s Price Performance</h2>
Shares of Acadia Healthcare have gained 19.2% in the past month compared with the industry&#39;s 8.5% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4d/75809.jpg?v=356746199" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Key Picks</h2>
ACHC currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the Medical space are LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>)&nbsp;, Avanos Medical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avns#NYSE">AVNS</a>) and The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>). While LeMaitre Vascular sports a Zacks Rank #1 (Strong Buy), Avanos Medical and Ensign Group carry a Zacks Rank #2 (Buy) at present.
LeMaitre Vascular&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 8.87%. The Zacks Consensus Estimate for LMAT&#39;s 2024 earnings implies an improvement of 37% while the same for revenues indicates growth of 13% from the respective 2023 figures.
The Zacks Consensus Estimate for LMAT&#39;s&nbsp; earnings has moved 4.5% north in the past 30 days. Shares of LeMaitre Vascular have gained 2.4% in the past month.
Avanos Medical&#39;s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 5.69%. The Zacks Consensus Estimate for AVNS&#39; 2024 earnings indicates a 35% rise from the 2023 figure.
The consensus mark for AVNS&#39;&nbsp; earnings has moved 0.7% north in the past 30 days. Shares of Avanos Medical have gained 6.1% in the past month.
Ensign Group&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.40%. The Zacks Consensus Estimate for ENSG&#39;s 2024 earnings indicates an 14.1% rise while the same for revenues implies an improvement of 13.1% from the respective 2023 reported figures.&nbsp;
The consensus mark for ENSG&#39;s earnings has moved up 0.7% in the past 30 days.&nbsp; Shares of Ensign Group have gained 1.8% in the past month.
<a href="https://www.zacks.com/stock/news/2328512/acadia-healthcare-expands-behavioral-health-services-in-iowa?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328512">To read this article on Zacks.com click here.</a>

Mid Cap

Health Care

Small Cap

Management

General

ACHC

AVNS

ENSG

Acadia Healthcare Expands Behavioral Health Services in Iowa

On August 26, 2024, LeMaitre Vascular, Inc. (the "Company"), announced that Joseph P. Pellegrino, Jr. will retire as an employee of the company, including as Chief Financial Officer, effective as of March 7, 2025, following the anticipated filing of the 2024 Fiscal Year 10-K. Mr. Pellegrino will remain on the Board of Directors. The Company thanks Mr. Pellegrino for his 19 years of executive service and is thrilled to retain his Board-level services going forward. Mr. Pellegrino was re-elected to the Board in June 2024 and will serve out the remainder of this term until June 2027. The Company will conduct a search for a replacement Chief Financial Officer and anticipates Mr. Pellegrino being involved in the hiring, selection and onboarding process. As of August 26, 2024, the Company reaffirms its August 1, 2024 financial guidance covering Q3 2024 and Full-Year 2024.

Lemaitre Vascular Announces Joseph P. Pellegrino, Jr. Will Retire As An Employee Of The Company As Well As CFO, Effective As Of March 7, 2025; Co Reaffirms August 1, 2024 Financial Guidance Covering Q3 2024 And Full-Year 2024

JMP Securities analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Market Outperform and raises the price target from $77 to $100.

JMP Securities Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $100

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $79 to $92.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $92

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Q3 2024 Guidance</td>
<td>Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Sales</td>
<td>$52.7mm - $54.7mm (Mid: $53.7mm, +13%, +14% Org.)</td>
<td>$216.8mm - $220.8mm (Mid: $218.8mm, +13%, + 13% Org.)</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>68.0%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Op. Income</td>
<td>$11.3mm - $12.7mm (Mid: $12.0mm, +31%) &nbsp;</td>
<td>$49.7mm - $52.5mm (Mid $51.1mm, +39%) (Mid: $51.1mm, +37% Ex-Special)&#x2A;</td>
</tr>
<tr>
<td>Op. Margin (Mid)</td>
<td>22%</td>
<td>23%</td>
</tr>
<tr>
<td>EPS</td>
<td>$0.42 - $0.46 (Mid: $0.44, +32%)</td>
<td>$1.82 - $1.91 (Mid: $1.86, +39%) (Mid: $1.86, +37% Ex-Special)&#x2A;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;Special charges in 2023 were related to the St. Etienne factory closure.

LeMaitre Vascular Sees Q3 EPS $0.42-$0.46 Vs $0.42 Est.; Revenue $52.7M-$54.7M Vs $52.35M Est.; FY24 EPS $1.82-$1.91 Vs $1.77 Est.; Revenue $216.8M-$220.8M Vs $215.05M Est.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.47 by 12.77 percent. The company reported quarterly sales of $55.849 million which beat the analyst consensus estimate of $54.986 million by 1.57 percent. This is a 11.44 percent increase over sales of $50.115 million the same period last year.

LeMaitre Vascular Q2 2024 GAAP EPS $0.53 Beats $0.47 Estimate, Sales $55.849M Beat $54.986M Estimate

GE HealthCare Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>), along with Heart Hospital of New Mexico at Lovelace Medical Center (HHNM), announced HHNM as the first location in the United States to install GE HealthCare&#39;s latest Allia Image Guided System Pulse. The Allia IGS Pulse system is expected to provide excellent image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVDs).
HHNM expects to use the Allia IGS Pulse system in its cardiac electrophysiology lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations and cardiac catherizations, among others.
The latest installation is expected to strengthen GE HealthCare&#39;s foothold in the CVD treatment space.
<h3>Significance of the Installation</h3>
According to a report by the American Heart Association, heart disease has been the leading cause of death in the United States for decades. Per the report, nearly half (48.6%) of all people over the age of 20 years have some type of CVD, including coronary heart disease, heart failure, stroke and, most notably, high blood pressure.
Per GE HealthCare&#39;s management, the collaboration with HHNM for the first U.S. installation of the Allia IGS Pulse System will likely address current healthcare challenges and provide optimal experiences for patients and their providers.
HHNM&#39;s management believes that as New Mexico&#39;s only hospital exclusively dedicated to heart care, it will be able to provide innovative treatment options for the patients and keep them close to home for care.
<h3>Industry Prospects</h3>
Per a report by MarketsandMarkets, the global electrophysiology market was valued at $8.2 billion in 2023 and is anticipated to reach $15.1 billion by 2028 at a CAGR of 13%. Factors like the increasing prevalence of CVDs and technological advancements are likely to drive the market.
Given the market potential, the latest installation is expected to provide a significant boost to GE HealthCare&#39;s business.
<h3>Recent Developments</h3>
This month, GE HealthCare, along with MediView XR Inc., announced the successful first installation and clinical cases using the OmnifyXR Interventional Suite at North Star Vascular and Interventional in Minneapolis, MN.
The same month, GE HealthCare inked an agreement with Salud Digna. The agreement aims to deploy digital solutions to improve the efficiency of care protocols for clinicians on Computed tomography, Magnetic resonance and ultrasound systems across Mexico.
Last month, GE HealthCare collaborated with Medis Medical Imaging. The collaboration is aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease. Both companies are expected to focus on the integration of Medis Quantitative Flow Ratio into GE HealthCare&#39;s cath lab environment built around the Allia Platform to enable a seamless user experience.
<h3>Price Performance</h3>
Shares of GE HealthCare have gained 1.6% in the past year against the industry&#39;s 26.4% decline. The S&amp;P 500 has witnessed 26.1% growth in the said time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/96/69509.jpg?v=1932984697" /> 
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Key Picks</h3>
Currently, GE HealthCare carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>) and Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%.
DaVita&#39;s shares have gained 47.9% compared with the industry&#39;s 16.4% rise in the past year.
LeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.5%. LMAT&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 10.1%.
LeMaitre Vascular has gained 19.8% against the industry&#39;s 1.8% decline in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab&#39;s shares have rallied 34.6% against the industry&#39;s 10.8% decline in the past year.
<a href="https://www.zacks.com/stock/news/2293112/ge-healthcare-s-gehc-new-tie-up-to-boost-cvd-workflow?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2293112">To read this article on Zacks.com click here.</a>

GEHC

GE HealthCare's New Tie-Up to Boost CVD Workflow

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.75, along with a high estimate of $100.00 and a low estimate of $75.00. This current average reflects an increase of 24.12% from the previous average price target of $66.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1717164022_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive LeMaitre Vascular is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$77.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to LeMaitre Vascular. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for LeMaitre Vascular's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into LeMaitre Vascular's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know LeMaitre Vascular Better</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Financial Milestones: LeMaitre Vascular's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 13.6%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: LeMaitre Vascular's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): LeMaitre Vascular's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.82%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For LeMaitre Vascular

Roth MKM analyst Jason Wittes reinstates LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Buy and announces $100 price target.

Roth MKM Reinstates Buy on LeMaitre Vascular, Announces $100 Price Target

Reports Q3 revenue $54.82M, consensus $53.5M. Chairman/CEO George LeMaitre (LMAT) said, "2024 is shaping up to be a year of healthy sales and profi...

LeMaitre reports Q3 diluted EPS 49c, consensus 43c

LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript

KeyBanc analyst Brett Fishbin maintained a Hold rating on Lemaitre Vascular (LMAT – Research Report) today. The company's shares closed yesterday a...

KeyBanc Remains a Hold on Lemaitre Vascular (LMAT)

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of $100.00. Th...

Lemaitre Vascular (LMAT) Gets a Buy from Stifel Nicolaus

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI – Research Report), Zymeworks (ZYME – Rese...

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Zymeworks (ZYME) and Lemaitre Vascular (LMAT)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a price tar...

Lemaitre Vascular: Strong Financial Performance and Positive Outlook Drive OUTPERFORM Rating

Barrington analyst Michael Petusky raised the firm's price target on LeMaitre (LMAT) to $93 from $92 and keeps an Outperform rating on the shares. ...

LeMaitre price target raised to $93 from $92 at Barrington

LeMaitre Vascular declares $0.16 dividend

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

Dividend Champion, Contender, And Challenger Highlights: Week Of November 17

AMAT

AMCR

ARTNA

BOTJ

BPOP

BWXT

CBAN

CCOI

CHCT

CIVB

CTSH

EVRG

FANG

FAST

FBIZ

FBMS

FCBC

FCPT

FELE

FMCB

FSBW

FXNC

GABC

HFWA

JBHT

LAND

LCII

LFUS

LSTR

MCHP

MKTX

MSBI

MSFT

NIDB

SBFG

SBSI

SIRI

STBA

TSCO

WAFD

WDFN

WTFC

ZION

ZYME

Press Releases

LeMaitre to Present at the 23rd Annual Needham Virtual Healthcare Conference

LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024

LeMaitre Q1 2024 Financial Results

LeMaitre to Present at the Jefferies Global Healthcare Conference

LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024

LeMaitre Q2 2024 Financial Results

LeMaitre to Participate at Upcoming Investor Conferences in September

LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024

LeMaitre Q3 2024 Financial Results

LeMaitre to Participate at Upcoming Investor Conferences in November

Artivion

Alphatec Holdings

AtriCure

Axonics

CeriBell

Conmed

Enovis

Paragon 28

Glaukos

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRadimed

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Inari Medical

NovoCure

Envista Holdings Corporation Common Stock

Envista Holdings

Orthofix Medical

Omnicell

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

TransMedics Gr

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Oppenheimer

Barrington Research

Cantor Fitzgerald

JMP Securities

Roth MKM

Comments

LeMaitre Vascular

Notizie

Ultime notizie per LeMaitre Vascular (NASDAQ:LMAT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO